Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

30-10-2014 | Genitourinary cancers | Book chapter | Article

6. New Imaging Techniques in the Staging of Urothelial Carcinoma of the Bladder

Authors: Ramdev Konijeti, M.D., Adam S. Kibel, M.D.

Publisher: Springer New York

Login to get access

Abstract

The surgical treatment of bladder cancer ranges from simple transurethral resection to radical cystectomy with or without perioperative chemotherapy. As such, staging is a key driver of therapy. While conventional imaging techniques clearly play a central role in the assessment of bladder cancer, assessment of disease extent could be improved. As such, multiple new imaging modalities have sought to improve staging and in doing so improve cure rates. The focus of this chapter will be to highlight the current state-of-the-art with respect to use of newer magnetic resonance (e.g. diffusion-weighted MRI (DW MRI), dynamic contrast-enhanced MRI (DCE MRI), MRI lymphography) and positron emission tomography (PET) techniques to improve assessment of local and metastatic disease.
Literature
1.
Baltaci S, et al. Computerized tomography for detecting perivesical infiltration and lymph node metastasis in invasive bladder carcinoma. Urol Int. 2008;81(4):399–402.PubMedCrossRef
2.
Caterino M, et al. Primary cancer of the urinary bladder: CT evaluation of the T parameter with different techniques. Abdom Imaging. 2001;26(4):433–8.PubMedCrossRef
3.
Cowan NC, Crew JP. Imaging bladder cancer. Curr Opin Urol. 2010;20(5):409–13.PubMedCrossRef
4.
Kundra V, Silverman PM. Imaging in oncology from the University of Texas M. D. Anderson Cancer Center. Imaging in the diagnosis, staging, and follow-up of cancer of the urinary bladder. AJR Am J Roentgenol. 2003;180(4):1045–54.PubMedCrossRef
5.
Paik ML, et al. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol. 2000;163(6):1693–6.PubMedCrossRef
6.
Voges GE, et al. Computerized tomography: an unreliable method for accurate staging of bladder tumors in patients who are candidates for radical cystectomy. J Urol. 1989;142(4):972–4.PubMed
7.
Yaman O, et al. Staging with computed tomography, transrectal ultrasonography and transurethral resection of bladder tumour: comparison with final pathological stage in invasive bladder carcinoma. Br J Urol. 1996;78(2):197–200.PubMedCrossRef
8.
Herr HW, Donat SM, Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol. 2007;177(1):75–9. discussion 79.PubMedCrossRef
9.
Dutta SC, et al. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol. 2001;166(2):490–3.PubMedCrossRef
10.
Stein JP, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666–75.PubMed
11.
Grossman HB, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66.PubMedCrossRef
12.
Moses KA, et al. Bladder cancer imaging: an update. Curr Opin Urol. 2011;21(5):393–7.PubMedCrossRef
13.
Silverman SG, Leyendecker JR, Amis Jr ES. What is the current role of CT urography and MR urography in the evaluation of the urinary tract? Radiology. 2009;250(2):309–23.PubMedCrossRef
14.
Matsuki M, et al. Diffusion-weighted MR imaging for urinary bladder carcinoma: initial results. Eur Radiol. 2007;17(1):201–4.PubMedCrossRef
15.
Abou-El-Ghar ME, et al. Bladder cancer: diagnosis with diffusion-weighted MR imaging in patients with gross hematuria. Radiology. 2009;251(2):415–21.PubMedCrossRef
16.
Avcu S, et al. The value of diffusion-weighted MRI in the diagnosis of malignant and benign urinary bladder lesions. Br J Radiol. 2011;84(1006):875–82.PubMedCentralPubMedCrossRef
17.
Watanabe H, et al. Preoperative T staging of urinary bladder cancer: does diffusion-weighted MRI have supplementary value? AJR Am J Roentgenol. 2009;192(5):1361–6.PubMedCrossRef
18.
El-Assmy A, et al. Bladder tumour staging: comparison of diffusion- and T2-weighted MR imaging. Eur Radiol. 2009;19(7):1575–81.PubMedCrossRef
19.
Takeuchi M, et al. Urinary bladder cancer: diffusion-weighted MR imaging–accuracy for diagnosing T stage and estimating histologic grade. Radiology. 2009;251(1):112–21.PubMedCrossRef
20.
Bouchelouche KB, Turkbey, Choyke PL. PET/CT and MRI in bladder cancer. J Cancer Sci Ther 2012;S14(1).
21.
Tuncbilek N, et al. Value of dynamic contrast-enhanced MRI and correlation with tumor angiogenesis in bladder cancer. AJR Am J Roentgenol. 2009;192(4):949–55.PubMedCrossRef
22.
Barentsz JO, et al. Staging urinary bladder cancer after transurethral biopsy: value of fast dynamic contrast-enhanced MR imaging. Radiology. 1996;201(1):185–93.PubMedCrossRef
23.
Scattoni V, et al. Dynamic gadolinium-enhanced magnetic resonance imaging in staging of superficial bladder cancer. J Urol. 1996;155(5):1594–9.PubMedCrossRef
24.
Ak I, Stokkel MP, Pauwels EK. Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours. J Cancer Res Clin Oncol. 2000;126(10):560–74.PubMedCrossRef
25.
Jana S, Blaufox MD. Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med. 2006;36(1):51–72.PubMedCrossRef
26.
Leskinen-Kallio S, et al. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin’s lymphoma: a PET study. J Nucl Med. 1991;32(6):1211–8.PubMed
27.
Anjos DA, et al. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med. 2007;48(5):764–70.PubMedCrossRef
28.
Kibel AS, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol. 2009;27(26):4314–20.PubMedCentralPubMedCrossRef
29.
Lodde M, et al. Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma. BJU Int. 2010;106(5):658–63.PubMedCrossRef
30.
Gofrit ON, et al. Contribution of 11C-choline positron emission tomography/computerized tomography to preoperative staging of advanced transitional cell carcinoma. J Urol. 2006;176(3):940–4. discussion 944.PubMedCrossRef
31.
Picchio M, et al. Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings. J Nucl Med. 2006;47(6):938–44.PubMed
32.
Ahlstrom H, et al. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol. 1996;37(2):180–5.PubMedCrossRef
33.
Vargas HA, et al. Prospective evaluation of MRI, (1)(1)C-acetate PET/CT and contrast-enhanced CT for staging of bladder cancer. Eur J Radiol. 2012;81(12):4131–7.PubMedCrossRef
34.
National Comprehensive Cancer Network. NCCN Guidelines Version 1. 2013 bladder cancer. 2013 [cited 2013 September 3]; Available from: http://​www.​nccn.​org/​professionals/​physician_​gls/​pdf/​bladder.​pdf
35.
Abbosh P, et al. Evaluation of alkaline phosphatase as a marker for bone metastasis in patients with muscle-invasive bladder cancer. J Urol. 2013;189(4 Suppl):e770.CrossRef
36.
Millikan R, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol. 2001;19(20):4005–13.PubMed
37.
Bellin MF, Roy C. Magnetic resonance lymphography. Curr Opin Urol. 2007;17(1):65–9.PubMedCrossRef
38.
Bellin MF, et al. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles–initial clinical experience. Radiology. 1998;207(3):799–808.PubMedCrossRef
39.
Deserno WM, et al. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology. 2004;233(2):449–56.PubMedCrossRef
40.
Thoeny HC, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol. 2009;55(4):761–9.PubMedCrossRef
41.
Drieskens O, et al. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging. 2005;32(12):1412–7.PubMedCrossRef
42.
Apolo AB, et al. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol. 2010;28(25):3973–8.PubMedCentralPubMedCrossRef
43.
Abbosh P, et al. Utility of FDG-PET/CT in identifying bone metastasis in patients with bladder cancer. J Urol. 2013;189(4 Suppl):e903.CrossRef
44.
Maurer T, et al. Diagnostic efficacy of [11C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy. Eur Urol. 2012;61(5):1031–8.PubMedCrossRef
45.
Golan S, et al. Comparison of 11C-choline with 18F-FDG in positron emission tomography/computerized tomography for staging urothelial carcinoma: a prospective study. J Urol. 2011;186(2):436–41.PubMedCrossRef
46.
Letocha H, et al. Positron emission tomography with L-methyl-11C-methionine in the monitoring of therapy response in muscle-invasive transitional cell carcinoma of the urinary bladder. Br J Urol. 1994;74(6):767–74.PubMedCrossRef
47.
Schoder H, et al. Initial results with (11)C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer. Mol Imaging Biol. 2012;14(2):245–51.PubMedCrossRef
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits